​

Gain Therapeutics (GANX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

GANX Stock Forecast

Gain Therapeutics (GANX) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $7.00, with a high of $10.00 and a low of $4.00. This represents a 234.93% increase from the last price of $2.09.

$1 $2 $3 $4 $5 $6 $7 $8 $9 $10 High: $10 Avg: $7 Low: $4 Last Closed Price: $2.09

GANX Stock Rating

Gain Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (85.71%), 1 Hold (7.14%), 1 Sell (7.14%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 1 1 12 Strong Sell Sell Hold Buy Strong Buy

GANX Forecast vs Benchmarks

TypeNameUpside
StockGain Therapeutics234.93%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.09$2.09$2.09
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 2533---6
Dec, 2433---6
Nov, 2423---5
Oct, 2423---5
Sep, 2423---5
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 09, 2022Chardan Capital$4.00$3.1526.98%91.39%
Nov 13, 2022Thomas ShraderBTIG$10.00$3.21211.53%378.47%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024Maxim GroupBuyBuyhold
Sep 03, 2024H.C. WainwrightBuyBuyhold
Jul 02, 2024H.C. WainwrightBuyBuyhold
Sep 12, 2023MacquarieOutperforminitialise
May 15, 2023Chardan CapitalBuyBuyhold
Dec 09, 2022Chardan CapitalBuyinitialise
Nov 14, 2022EF HuttonBuyBuyhold
Nov 13, 2022BTIGBuyBuyhold
Aug 19, 2022B. Riley SecuritiesNeutraldowngrade

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.37$-1.48$-1.71-----
Avg Forecast$-1.57$-1.41$-1.60$-0.96$-0.73$-1.01$-1.08$-1.07
High Forecast$-1.57$-1.41$-1.79$-1.04$-1.06$-1.18$-1.33$-1.07
Low Forecast$-1.57$-1.41$-1.39$-0.92$-0.53$-0.84$-0.83$-1.07
Surprise %-12.74%4.96%6.88%-----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$164.99K$140.11K$55.18K-----
Avg Forecast$149.00K$125.00K$276.00K$33.33K$66.67K$225.00K$225.00K$100.29M
High Forecast$149.00K$125.00K$118.28K$33.33K$66.67K$225.00K$225.00K$100.29M
Low Forecast$149.00K$125.00K$591.43K$33.33K$66.67K$225.00K$225.00K$100.29M
Surprise %10.73%12.09%-80.01%-----

Net Income Forecast

$-25M $-21M $-17M $-13M $-9M $-5M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-13.89M$-17.59M$-22.27M-----
Avg Forecast$-20.47M$-18.37M$-22.27M$-12.73M$-10.34M$-13.14M$-14.05M$-13.92M
High Forecast$-20.47M$-18.37M$-23.24M$-13.55M$-13.83M$-15.31M$-17.30M$-13.92M
Low Forecast$-20.47M$-18.37M$-18.13M$-11.92M$-6.85M$-10.97M$-10.80M$-13.92M
Surprise %-32.16%-4.23%------

GANX Forecast FAQ

Is Gain Therapeutics stock a buy?

Gain Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Gain Therapeutics is a favorable investment for most analysts.

What is Gain Therapeutics's price target?

Gain Therapeutics's price target, set by 14 Wall Street analysts, averages $7 over the next 12 months. The price target range spans from $4 at the low end to $10 at the high end, suggesting a potential 234.93% change from the previous close price of $2.09.

How does Gain Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Gain Therapeutics stock forecast shows a 234.93% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Gain Therapeutics over the past three months?

  • January 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Gain Therapeutics’s EPS forecast?

Gain Therapeutics's average annual EPS forecast for its fiscal year ending in December is -0.96 for 2024, a -43.86% decrease from the reported $-1.71 in 2023. The prediction for 2025 is $-0.73, $-1.01 for 2026, $-1.08 for 2027, and $-1.07 for 2028.

What is Gain Therapeutics’s revenue forecast?

Gain Therapeutics's average annual revenue forecast for its fiscal year ending in December is $33.33K for 2024, a -39.59% decrease from the reported $55.18K in 2023. The forecast for 2025 is $66.67K, $225K for 2026, $225K for 2027, and $100.29M for 2028.

What is Gain Therapeutics’s net income forecast?

For its fiscal year ending in December, Gain Therapeutics's average annual net income forecast is $-12.731M for 2024, reflecting a -42.83% decrease from the reported $-22.268M in 2023. The projection for 2025 is $-10.34M, $-13.141M for 2026, $-14.052M for 2027, and $-13.922M for 2028.